Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Anales De Medicina Interna (Madrid, Spain : 1984)|August 16, 2001
[Varicella pneumonia in the adult. Study of 9 cases]C Paytubí, E Negredo, S Ferrer, et al.
HIV Medicine|July 4, 2017
Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV-1-infected subjects with dyslipidaemiaP Echeverría, A Bonjoch, J Puig, et al.
Medicine|August 12, 2016
Impact of protease inhibitors on the evolution of urinary markers: Subanalyses from an observational cross-sectional studyAnna Bonjoch, Jordi Puig, Nuria Pérez-Alvarez, et al.
Antimicrobial Agents and Chemotherapy|August 27, 2014
Differential subcutaneous adipose tissue gene expression patterns in a randomized clinical trial of efavirenz or lopinavir-ritonavir in antiretroviral-naive patientsL Egaña-Gorroño, E Martínez, P Domingo, et al.
HIV Clinical Trials|February 11, 2009
Transient treatment exclusively containing nucleoside analogue reverse transcriptase inhibitors in highly antiretroviral-experienced patients preserves viral benefit when a fully active therapy was initiatedA Bonjoch, M J Buzon, J M Llibre, et al.
AIDS (London, England)|April 19, 2000
Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppressionL Ruiz, J Martinez-Picado, J Romeu, et al.
AIDS Care|August 30, 2008
Sustained antiretroviral treatment adherence in survivors of the pre-HAART era: attitudes and beliefsC R Fumaz, J A Muñoz-Moreno, J Moltó, et al.
The Journal of Antimicrobial Chemotherapy|April 4, 2017
Variable endothelial cell function restoration after initiation of two antiretroviral regimens in HIV-infected individualsP Echeverría, E Gómez-Mora, S Roura, et al.
HIV Medicine|May 20, 2008
Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot studyJ M Llibre, A Bonjoch, J Iribarren, et al.
HIV Medicine|May 7, 2015
Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 yearsE Negredo, A Bonjoch, N Pérez-Álvarez, et al.
Pageof 3